Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Quercetin  COVID-19 treatment studies for Quercetin  C19 studies: Quercetin  Quercetin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery 33% Improvement Relative Risk CRP reduction 39% Viral clearance 50% Khan et al. NCT05130671 Quercetin RCT EARLY TREATMENT Is early treatment with quercetin+curcumin and vitamin D beneficial for COVID-19? RCT 50 patients in Pakistan (September - November 2021) Improved viral clearance with quercetin+curcumin and vitamin D (p=0.0086) Khan et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.898062 Favors quercetin Favors control
Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19—Results From a Pilot Open-Label, Randomized Controlled Trial
Khan et al., Frontiers in Pharmacology, doi:10.3389/fphar.2022.898062, NCT05130671 (history)
Khan et al., Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate.., Frontiers in Pharmacology, doi:10.3389/fphar.2022.898062, NCT05130671
May 2022   Source   PDF  
  All Studies   Meta
RCT 50 COVID+ outpatients in Pakistan, 25 treated with curcumin, quercetin, and vitamin D, showing significantly faster viral clearance, significantly improved CRP, and faster resolution of acute symptoms (p=0.154). 168mg curcumin, 260mg quercetin and 360IU cholecalciferol.
risk of no recovery, 33.3% lower, RR 0.67, p = 0.15, treatment 10 of 25 (40.0%), control 15 of 25 (60.0%), NNT 5.0.
relative CRP reduction, 39.1% better, RR 0.61, p = 0.006, treatment 25, control 25.
risk of no viral clearance, 50.0% lower, RR 0.50, p = 0.009, treatment 10 of 25 (40.0%), control 20 of 25 (80.0%), NNT 2.5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Khan et al., 1 May 2022, Randomized Controlled Trial, Pakistan, peer-reviewed, 7 authors, study period 2 September, 2021 - 28 November, 2021, this trial uses multiple treatments in the treatment arm (combined with curcumin and vitamin D) - results of individual treatments may vary, trial NCT05130671 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperQuercetinAll
Abstract: CLINICAL TRIAL published: 07 June 2022 doi: 10.3389/fphar.2022.898062 Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19 —Results From a Pilot Open-Label, Randomized Controlled Trial Amjad Khan 1,2*, Somia Iqtadar 3, Sami Ullah Mumtaz 3, Michael Heinrich 4, Domingo A. Pascual-Figal 5,6, Shona Livingstone 7 and Sajid Abaidullah 3 1 Edited by: Yusof Kamisah, Universiti Kebangaan Malaysia, Malaysia Reviewed by: Ruben Manuel Luciano Colunga Biancatelli, Old Dominion University, United States Syed Mohammed Basheeruddin Asdaq, University of Almaarefa, Saudi Arabia *Correspondence: Amjad Khan Specialty section: This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology Received: 16 March 2022 Accepted: 27 April 2022 Published: 07 June 2022 Citation: Khan A, Iqtadar S, Mumtaz SU, Heinrich M, Pascual-Figal DA, Livingstone S and Abaidullah S (2022) Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID19—Results From a Pilot Open-Label, Randomized Controlled Trial. Front. Pharmacol. 13:898062. doi: 10.3389/fphar.2022.898062 INEOS Oxford Institute for AMR Research, University of Oxford, Oxford, United Kingdom, 2Department of Biochemistry, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan, 3Department of Medicine, King Edward Medical University, Lahore, Pakistan, 4UCL School of Pharmacy, University of London, London, United Kingdom, 5Department of Cardiology, University of Murcia Hospital Universitario Virgen de la Arrixaca Murcia, Murcia, Spain, 6Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, 7School of medicine, University of Dundee, Dundee, United Kingdom Background: Curcumin, quercetin, and vitamin D3 (cholecalciferol) are common natural ingredients of human nutrition and reportedly exhibit promising anti-inflammatory, immunomodulatory, broad-spectrum antiviral, and antioxidant activities. Objective: The present study aimed to investigate the possible therapeutic benefits of a single oral formulation containing supplements curcumin, quercetin, and cholecalciferol (combinedly referred to here as CQC) as an adjuvant therapy for early-stage of symptomatic coronavirus disease 2019 (COVID-19) in a pilot open-label, randomized controlled trial conducted at Mayo Hospital, King Edward Medical University, Lahore, Pakistan. Methods: Reverse transcriptase polymerase chain reaction (RT-PCR) confirmed, mild to moderate symptomatic COVID-19 outpatients were randomized to receive either the standard of care (SOC) (n = 25) (control arm) or a daily oral co-supplementation of 168 mg curcumin, 260 mg quercetin, and 9 µg (360 IU) of cholecalciferol, as two oral soft capsules b.i.d. as an add-on to the SOC (n = 25) (CQC arm) for 14 days. The SOC includes paracetamol with or without antibiotic (azithromycin). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test, acute symptoms, and biochemistry including C-reactive protein (CRP), D-dimer, lactate dehydrogenase, ferritin, and complete blood count were evaluated at baseline and follow-up day seven. Results: Patients who received the CQC adjuvant therapy showed expedited negativization of the SARS-CoV-2 RT-PCR test, i.e., 15 (60.0%) vs. five (20.0%) of the control arm, p = 0.009. COVID-19- associated acute symptoms were rapidly resolved in the..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop